iHub My Stocks Activity
Ticker Buzz Cloud
Most Followed Members
Data Tools >
Price & News Alerts
Markets in 3D
More Tools >
My Image Gallery
Personal Finance Q&A
Medical - Drugs
QIAGEN N.V. (QGEN)
Add QGEN Price Alert
Search This Board:
6/15/2017 11:10:30 AM
- Board type:
- Posts Today:
Qiagen N.V. ~Nasdaq Bio~ QGEN Due Diligence
QGEN Company Overview & Description
QIAGEN N.V. is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA, and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analysis.
We have developed and market more than 500 consumable products and automated solutions. The company provides these products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics.
QIAGEN employs more than 3,800 people in over 35 locations worldwide.
QIAGEN was founded 1984 as a spin-off at the University of Düsseldorf. Since then the company has continuously developed and turned into what is today the world's leading provider for innovative sample and assay technologies for research in molecular diagnostics, applied testing, pharma and academic research.
QGEN Key Company Management
Peer M. Schatz Managing Director, Chief Executive Officer,
has spearheaded the development of QIAGEN's strategic focus on sample and assay technologies and the efforts to bring these technologies to customers in molecular diagnostics, applied testing, academia and the pharmaceutical industry. Mr. Schatz joined QIAGEN in 1993, when the company had just 30 employees and revenues of approximately $2 million. Under his direction, QIAGEN has grown to employ more than 3,700 people in over 35 locations around the world and boasts revenues of more than US$ 1 billion. He has also led QIAGEN to listings on the NASDAQ, making QIAGEN the first German company to do so, as well as the Frankfurt Stock Exchange. Mr. Schatz, a Swiss and Austrian citizen, was born in New York and grew up in the United States and Switzerland. He studied business and social sciences at the University of St. Gallen, Switzerland, where he graduated with a Masters in Finance in 1989. He later obtained a Masters of Business Administration (MBA) from the University of Chicago Graduate School in Business in 1990. Prior to 1993, Mr. Schatz held various positions at Sandoz AG and Computerland and participated in the foundation of startup companies in the computer and software trading industry in both Europe and the United States. He is a member of the German Corporate Governance Commission. He also serves as a member of the Managing Board of PMS Asset Management GmbH and holds director positions of AdvaMedDx (Unites States In-Vitro diagnostics industry organization) and ALSSA (United States Analytical & Life Science Systems Associaton).
Roland Sackers (born 1968) is Chief Financial Officer and Managing Director of QIAGEN N.V.
In this role, Mr. Sackers heads the creation and execution of a long-term financial plan which enables the Company to execute its accelerated growth strategy.
This roadmap includes numerous M&A transactions, which Sackers enabled and supported through financing activities both on the equity and the debt capital side valued at more than $2 billion. It has led to strong revenue streams and significant profit growth under his tenure.
Mr. Sackers has earned a degree as Diplom-Kaufmann from the Westfälische Wilhelms-Universität Münster, Germany. He joined the company in 1999 and has been Chief Financial Officer since 2004. In 2006, Mr. Sackers was named Managing Director. Prior to joining QIAGEN, he acted as an auditor with Arthur Andersen.
Roland Sackers is a board member of the industry association BIO Deutschland and QIAGEN's representative on the Board of Eurofins Genomics B.V. He is also a Non-Executive Director and Chair of the Audit Committee of Immunodiagnostic Systems Holding (IDS), a leading producer of immunological tests for research and diagnostic applications publicly listed in the United Kingdom, as well as Member of the Board and Head of the Audit Committee of Ipsogen S.A., a global leader in molecular profiling and personalized healthcare diagnostics publicly listed in France
View the complete executive committee:
QGEN Contact Info
Venlo, 5911 KJ
Phone: 31 77 320 8400
Fax: 31 77 320 8409
Business & Technology
Dr. Helmut Hilbert
QIAGEN Strasse 1
40724 Hilden, Germany
Tel: +49 (0)2103-29-16221
Fax: +49 (0)2103-29-26221
For more information about QIAGEN's business activities, send an e-mail to IR@QIAGEN.com or call +49 (2103) 29-11710 and ask for Investor Relations.
QIAGEN Strasse 1
40724 Hilden, Germany
Phone: +49 (2103) 29-11710
View full contact info:
27220 Turnberry Lane
Valencia, CA 91355
Hours: Normal business hours are 6:00 a.m. - 5:00 p.m. (PST) weekdays.
Technical Service: 800-DNA-PREP (800-362-7737)
Customer Care: 800-426-8157
QGEN Recent Developments
Frankfurt , Prime Standard: QIA Chart:
QGEN Products & Services
Financial Reporting/Disclosure & Security Details
QGEN follows under these quidelines on the Nasdaq information market tier and Frankfurt tier under the symbol Frankfurt , Prime Standard: QIA
Investigate more @
for more due diligence.
Under Dutch law, a company can issue shares up to its authorized share capital provided for in its articles of association, which authorized share capital cannot be more than five times the issued share capital.
Market Value1: 3.53B
Shares Outstanding: 234.12M
Common Shares, 0.01 EUR par value, authorized-410,000 shares, issued and outstanding-234,118 and 233,115 shares in 2011 and 2010, respectively
American Stock Transfer & Trust Company
6201 15 th Avenue
Brooklyn, NY 11219
Shareholder Services: Phone: +1 (718) 921-8124
Restricted Share Transfers: Phone: +1 (718) 921-8257
Reporting Status: U.S. Registered & Reporting: SEC Filer
Audited Financials: 6k filier
Fiscal Year End: 12/31
OTC Market Tier: Nasdaq/Frankfurt
SIC - Industry Classification: # 2836
Business Status Development Stage Company: HealthCare/Services
Incorporated In: Venlo, the Netherlands
New & Secondary Issue=6-96 3,350,000 shs at $12 by Goldman, Sachs & Co. et al
Capital Change=shs increased by 4 for 1 split. Ex-date=07/14/2000. Rec date=07/03/2000. Pay date=07/13/2000
OTC Disclosure last 10Q reported on a 6K Nov 14, 2011 period ending Sept 30, 2011
Before You Invest - Investigate! Always do your own due diligence
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing.
Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy.
Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, QGEN website
QGEN Detailed Quote
QGEN News: QIAGEN Announces High Accuracy of Bioinformatics Solutions in Women's Health Genetic Screening
10/19/2017 04:36:00 PM
QGEN News: QIAGEN N.V. to Report Third Quarter and First Nine Months of 2017 Results
10/16/2017 06:20:00 AM
QGEN News: QIAGEN Bioinformatics and NGS Solutions Enable Genomic Breakthroughs
10/12/2017 04:05:00 PM
QGEN News: QIAGEN and CENTOGENE to Collaborate in Bioinformatics for Genetic Diseases
10/09/2017 04:05:00 PM
QGEN News: QIAGEN Launches Fourth-generation QuantiFERON®-TB Gold Plus in the U.S.
10/05/2017 04:05:00 PM
Post New Msg
My Stocks (2)
What "pharmaceutical company" is QGEN and HTBM doing
06/15/17 11:10:30 AM
$QGEN DD Notes ~ http://www.ddnotesmaker.com/QGEN
12/28/14 03:48:42 PM
7:16AM Qiagen announces two agreements adding 'promising' new
05/31/13 10:25:10 AM
QIAGEN (QGEN) and Bayer (BAYRY) HealthCare signed a
10/25/12 04:26:53 PM
QGEN downgraded to Market Perform from Outperform at
04/29/12 08:49:38 AM
QIAGEN N.V. (QGEN) 1Q 2012 Earnings Call April
04/29/12 08:48:02 AM
posted, pending or
02/02/12 02:58:05 AM
QIAGEN Reports Fourth Quarter and Full-Year 2011 Results
01/31/12 04:17:38 PM
2/1/12 Webcast of QGEN Fourth Quarter and Year
01/25/12 12:25:10 PM
Watch inventory? Why Qiagen May Be About to
01/23/12 08:32:22 AM
QGEN chart: new higher high
01/18/12 09:17:08 AM
ty was much needed, all stocks deserve a home:)
01/15/12 01:26:06 AM
VERY Nice iBox & Due Diligence. Thanks.
01/14/12 11:00:38 AM
ibox is updated:) enjoy
01/13/12 10:30:37 PM
working on it as we speak:)
01/13/12 10:24:27 AM
Way to go. B'marked. Now I know there
01/13/12 10:23:09 AM
QGEN contact info: Qiagen NV
01/13/12 08:14:31 AM
01/13/12 08:13:37 AM
01/13/12 08:12:35 AM
QGEN was a much needed board: QIAGEN
01/13/12 08:06:44 AM
Post New Msg
My Stocks (2)
© 2017 InvestorsHub.Com, Inc.
Terms of Service
Advertise With Us
Stock Market 101
Investor Help Forum
Personal Finance Q&A
iHub on Facebook
iHub on Twitter
iHub iPhone/iPad App
iHub Android App
iHub BlackBerry App